[
  {
    "ts": null,
    "headline": "Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns",
    "summary": "If you are wondering whether Vertex Pharmaceuticals' current share price gives you a fair entry point, this article will walk you through what the numbers say about its value. The stock last closed at US$470.31, with returns of 2.0% over 7 days, 6.6% over 30 days, 4.0% year to date, 59.8% over 3 years and 116.7% over 5 years, while the 1 year return sits close to flat at a 0.3% decline. Recent headlines around Vertex have continued to focus on its position in pharmaceuticals and biotech...",
    "url": "https://finnhub.io/api/news?id=d555daf18313bd7bc27d38f35182e150087850e4a3d9411dd125aaa529ac1f91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771539134,
      "headline": "Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns",
      "id": 139152826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "If you are wondering whether Vertex Pharmaceuticals' current share price gives you a fair entry point, this article will walk you through what the numbers say about its value. The stock last closed at US$470.31, with returns of 2.0% over 7 days, 6.6% over 30 days, 4.0% year to date, 59.8% over 3 years and 116.7% over 5 years, while the 1 year return sits close to flat at a 0.3% decline. Recent headlines around Vertex have continued to focus on its position in pharmaceuticals and biotech...",
      "url": "https://finnhub.io/api/news?id=d555daf18313bd7bc27d38f35182e150087850e4a3d9411dd125aaa529ac1f91"
    }
  },
  {
    "ts": null,
    "headline": "Casgevy Rollout And Pipeline Progress Reshape CRISPR Therapeutics Investment Case",
    "summary": "CRISPR Therapeutics (NasdaqGM:CRSP) reports significant progress in the commercial rollout of Casgevy, its approved gene editing therapy for sickle cell disease. Patient initiations for Casgevy have nearly tripled year over year, with reimbursement now covering about 90% of eligible U.S. patients. The company and its partner Vertex Pharmaceuticals are expanding Casgevy access in international markets. CRISPR Therapeutics also highlights updates across its clinical pipeline, including liver...",
    "url": "https://finnhub.io/api/news?id=d616c684f6052843c93b38951f7c724b920bfd96b921f3a273022044c639b021",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771524628,
      "headline": "Casgevy Rollout And Pipeline Progress Reshape CRISPR Therapeutics Investment Case",
      "id": 139151507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics (NasdaqGM:CRSP) reports significant progress in the commercial rollout of Casgevy, its approved gene editing therapy for sickle cell disease. Patient initiations for Casgevy have nearly tripled year over year, with reimbursement now covering about 90% of eligible U.S. patients. The company and its partner Vertex Pharmaceuticals are expanding Casgevy access in international markets. CRISPR Therapeutics also highlights updates across its clinical pipeline, including liver...",
      "url": "https://finnhub.io/api/news?id=d616c684f6052843c93b38951f7c724b920bfd96b921f3a273022044c639b021"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Broadens Beyond Cystic Fibrosis As CASGEVY And Pipeline Take Shape",
    "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio beyond cystic fibrosis. The company is ramping up CASGEVY gene-editing treatments in hematology, with patients now receiving the therapy. Vertex also provided updates on new pain management therapies and hematology programs that are contributing to revenue. Vertex, long known for its cystic fibrosis franchise, is expanding into gene-editing and hematology as CASGEVY...",
    "url": "https://finnhub.io/api/news?id=0aaa1c6923b83710ccd497db01a385b15c845535a3afce6233fb539fdef7f4f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771524579,
      "headline": "Vertex Broadens Beyond Cystic Fibrosis As CASGEVY And Pipeline Take Shape",
      "id": 139151508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio beyond cystic fibrosis. The company is ramping up CASGEVY gene-editing treatments in hematology, with patients now receiving the therapy. Vertex also provided updates on new pain management therapies and hematology programs that are contributing to revenue. Vertex, long known for its cystic fibrosis franchise, is expanding into gene-editing and hematology as CASGEVY...",
      "url": "https://finnhub.io/api/news?id=0aaa1c6923b83710ccd497db01a385b15c845535a3afce6233fb539fdef7f4f2"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows",
    "summary": "Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.",
    "url": "https://finnhub.io/api/news?id=da3188aa8e0759e034241fa5573333ce75de63ea1fcc41657ef24330524c30d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771522320,
      "headline": "CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows",
      "id": 139162591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.",
      "url": "https://finnhub.io/api/news?id=da3188aa8e0759e034241fa5573333ce75de63ea1fcc41657ef24330524c30d7"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit",
    "summary": "CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its allogeneic CAR-T program zugo-cel (formerly CTX112) and outlining a strategy that includes combinati",
    "url": "https://finnhub.io/api/news?id=36072c05c82cb990d2daeaee6a481aa4977101461de817007bc5e6293dd52ea5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771503368,
      "headline": "CRISPR Therapeutics touts zugo-cel CAR-T gains, eyes autoimmune expansion at Citi oncology summit",
      "id": 139146335,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its allogeneic CAR-T program zugo-cel (formerly CTX112) and outlining a strategy that includes combinati",
      "url": "https://finnhub.io/api/news?id=36072c05c82cb990d2daeaee6a481aa4977101461de817007bc5e6293dd52ea5"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call",
    "summary": "Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from recently launched products in hematology and pain management. Management pointed to disciplined commercial execution and progress in diversifying the revenue base as key themes. CEO Reshma Kewalramani highlighted, “We are well positioned to deliver on the significant opportunities in front of us and drive",
    "url": "https://finnhub.io/api/news?id=33692463b275f4b1086eea88514b6f7d4074920e3e382927057fee74c32705c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771479469,
      "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call",
      "id": 139145215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from recently launched products in hematology and pain management. Management pointed to disciplined commercial execution and progress in diversifying the revenue base as key themes. CEO Reshma Kewalramani highlighted, “We are well positioned to deliver on the significant opportunities in front of us and drive",
      "url": "https://finnhub.io/api/news?id=33692463b275f4b1086eea88514b6f7d4074920e3e382927057fee74c32705c4"
    }
  },
  {
    "ts": null,
    "headline": "1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down",
    "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
    "url": "https://finnhub.io/api/news?id=acb5db7a87a7b2df915b2ca5d27e61b28fb38d0c679f0777250ee3b6dd4f6b9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771475784,
      "headline": "1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down",
      "id": 139153605,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
      "url": "https://finnhub.io/api/news?id=acb5db7a87a7b2df915b2ca5d27e61b28fb38d0c679f0777250ee3b6dd4f6b9c"
    }
  }
]